Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study

Abstract Background This phase 1b study evaluated the pharmacokinetics, safety, and antiviral effects of the respiratory syncytial virus (RSV)–specific fusion inhibitor JNJ-53718678 (JNJ-8678) in hospitalized RSV-infected patients aged > 1 to ≤24 months. Methods Patients categorized by age (cohor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases 2020-12, Vol.71 (10), p.e594-e603
Hauptverfasser:	Martinón-Torres, Federico, Rusch, Sarah, Huntjens, Dymphy, Remmerie, Bart, Vingerhoets, Johan, McFadyen, Katie, Ferrero, Fernando, Baraldi, Eugenio, Rojo, Pablo, Epalza, Cristina, Stevens, Marita
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antiviral Agents - therapeutic use Double-Blind Method Humans Imidazolidines - therapeutic use Indoles - therapeutic use Infant Online Only Respiratory Syncytial Virus Infections - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Background This phase 1b study evaluated the pharmacokinetics, safety, and antiviral effects of the respiratory syncytial virus (RSV)–specific fusion inhibitor JNJ-53718678 (JNJ-8678) in hospitalized RSV-infected patients aged > 1 to ≤24 months. Methods Patients categorized by age (cohort 1: ≥6 to ≤24 months; cohort 2: ≥3 to 1 to
ISSN:	1058-4838 1537-6591
DOI:	10.1093/cid/ciaa283